Altogether, this study provides several lines of evidence that splicing modulation holds potential as novel therapeutic option for AML patients carrying FLT3/ITD with high AR and/or long ITD length, who currently suffer from poor treatment outcome. This evidence concerns the gene FLT3 and acute myeloid leukemia.